|
Dear Employees:
I am pleased to announce today the senior
leadership team for the new Pfizer, described in detail in the attachment.
Collectively, these experienced and highly capable leaders from both
companies will comprise the strongest management team in our industry.
As our industry is increasingly characterized
by globalization, dramatic scientific advances, and a changing customer
base, the management strength of our new company will be a critically
important strategic advantage. In making these decisions, we have adhered
to the guiding principles of openness, transparency, and timeliness.
These principles are based on the companies' shared values.
Today's announcements follow careful analysis,
constructive debate, and an unwavering focus on the needs of the business.
The new structure represents either highly successful current operating
models, such as our global pharmaceuticals and consumer products businesses,
or new models, such as our reorganized Pfizer Global Research and Development
division. In all cases, we have captured what we believe to be the best
practices of both companies.
The new Pfizer will consist of four main
operating units:
- Pfizer Pharmaceuticals Group (PPG)
will include our U.S. and global human pharmaceutical organizations,
our global drug manufacturing operation, and the Capsugel capsule
manufacturing operation. Hank McKinnell will continue as President
of PPG, in addition to his duties as President and Chief Operating
Officer of Pfizer Inc.
- Warner-Lambert Consumer Division
will include over-the-counter health care products, confectionery
products, shaving products, and aquarium products. Morgan Morton will
be President of the Warner-Lambert Consumer Division and will also
be named Senior Vice President, Pfizer Inc. Morgan is currently Senior
Vice President, Warner-Lambert, and President of Warner-Lambert's
Consumer Healthcare Sector.
- Pfizer Animal Health Group will
include our companion animal and livestock businesses. Brian Barrett
will continue as President of the Pfizer Animal Health Group.
- Pfizer Global Research and Development
will operate in R&D locations in Alameda, California; La Jolla,
California; Ontario, Canada; Groton, Connecticut; Amboise, France;
Fresnes, France; Frieiburg, Germany; Ann Arbor, Michigan; Holland,
Michigan; Cambridge, UK; Eastleigh, UK; Sandwich, UK; Nagoya, Japan;
Tokyo, Japan; and all the supporting facilities across the world.
Pharmaceutical Delivery Systems will continue in Morris Plains, New
Jersey until it transitions to Ann Arbor in 2001. John Niblack will
be President of Pfizer Global Research and Development and will also
continue as Vice Chairman of Pfizer Inc.
I'd like to commend the hard work of our
Integration Steering Committee-especially its leaders, Hank McKinnell
and Tony Wild. In addition, both John Niblack and Morgan Morton have
provided outstanding leadership throughout the integration.
It's important to note that senior leadership
selection is separate from the process-described last week in a letter
from Hank McKinnell-of determining those administrative sites where
the new Pfizer's operations will be based.
I would also like to acknowledge several
Warner-Lambert officers who have announced their intention to retire.
These individuals helped build Warner-Lambert into the world-class company
that it is today, and they will continue to make valuable contributions
throughout the integration process. A number of other senior leaders
are still considering opportunities with the new Pfizer.
The new Pfizer will succeed because we are
determined to bring together the best people and practices from both
organizations. Our new leadership team and operating structure is a
major step toward achieving this goal. The next step will be additional
management announcements, which will be made by divisional and functional
leaders over the next several weeks.
Together, we will be focused more than ever
on meeting customer and patient needs, delivering shareholder value,
and providing unprecedented opportunities for our people.
Sincerely,
William C. Steere, Jr.
# # # #
PLEASE NOTE:
The appointments listed
below will take effect immediately following the close of the merger,
which is expected to occur in late May.
CORPORATE MANAGEMENT COMMITTEE
The Corporate Management Committee of the
new Pfizer will include the following:
- William C. Steere, Jr., will continue
as Chairman and CEO, Pfizer Inc.
- Henry A. McKinnell, Ph.D., will continue
as President and Chief Operating Officer, Pfizer Inc, and President,
Pfizer Pharmaceuticals Group. He will report to Mr. Steere.
- John F. Niblack, Ph.D., will continue
as Vice Chairman of Pfizer Inc, and will also be named President of
Pfizer Global Research and Development. He will report to Mr. Steere.
- C. L. Clemente will continue as Executive
Vice President, Corporate Affairs; and Secretary and Corporate Counsel,
Pfizer Inc. He will report to Mr. Steere.
- Peter B. Corr, Ph.D., will be named Senior
Vice President, Pfizer Inc, Executive Vice President, Pfizer Global
Research and Development, and President, Worldwide Development. He
is currently Vice President, Warner-Lambert; and President, Warner-Lambert/Parke-Davis
Pharmaceutical Research and Development. Dr. Corr will report to Dr.
Niblack.
- Karen L. Katen will continue as Senior
Vice President, Pfizer Inc; Executive Vice President, Pfizer Pharmaceuticals
Group; and President, U.S. Pharmaceuticals. She will report to Dr.
McKinnell.
- Paul S. Miller will continue as Executive
Vice President and General Counsel, Pfizer Inc. He will report to
Mr. Steere.
- George M. Milne, Jr., Ph.D., will continue
as Senior Vice President, Pfizer Inc, and will also be named Executive
Vice President, Pfizer Global Research and Development, and President,
Worldwide Strategic and Operations Management. He is currently Senior
Vice President, Pfizer Inc, and President, Central Research. Dr. Milne
will report to Dr. Niblack.
- S. Morgan Morton will be named Senior
Vice President, Pfizer Inc, and President, Warner-Lambert Consumer
Division. He is currently Senior Vice President, Warner-Lambert, and
President of Warner-Lambert's Consumer Healthcare Sector. Mr. Morton
will report to Dr. McKinnell.
- William J. Robison, will continue as Executive
Vice President, Employee Resources, Pfizer Inc. He will report to
Mr. Steere.
- David L. Shedlarz will continue as Executive
Vice President and Chief Financial Officer, Pfizer Inc. He will report
to Mr. Steere.
As previously announced, Lodewijk J.R. de
Vink, Warner-Lambert's Chairman, President, and Chief Executive Officer,
and Anthony H. Wild, Ph.D., Executive Vice President, Warner-Lambert,
and President, Pharmaceutical Sector, have made personal decisions not
to remain with the company after the closing.
Additionally, the following corporate officers
of Warner-Lambert have announced their plans to retire after the closing:
Raymond M. Fino, Senior Vice President, Human Resources; Philip M. Gross,
Senior Vice President, Strategic Management Processes; Gregory L. Johnson,
Senior Vice President and General Counsel; Richard W. Keelty, Senior
Vice President, Public Affairs; and Ernest J. Larini, Chief Financial
Officer and Executive Vice President, Administration.
PFIZER PHARMACEUTICALS GROUP
Dr. McKinnell will continue as President
of Pfizer Pharmaceuticals Group (PPG). The PPG Leadership Team will
include the following:
- Peter C. Brandt, Senior Vice President
Finance, Planning & Business Development, Pfizer Pharmaceuticals Group
will continue in that position.
- Joseph M. Feczko, M.D., Senior Vice President,
Medical & Regulatory Operations, Pfizer Pharmaceuticals Group, will
continue in that position.
- Gary N. Jortner, Vice President, Pfizer
Inc, and Senior Vice President, Product Development, Pfizer Pharmaceuticals
Group, will continue in that position.
- Karen L. Katen will continue as Senior
Vice President, Pfizer Inc; Executive Vice President, Pfizer Pharmaceuticals
Group; and President, U.S. Pharmaceuticals.
- J. Patrick Kelly, Vice President, Pfizer
Inc, and Senior Vice President, Worldwide Marketing, Pfizer Pharmaceuticals
Group, will continue in that position.
- Robert W. Norton, Senior Vice President,
Employee Resources, Pfizer Pharmaceuticals Group, will continue in
that position.
- W. Hugh O'Connor, Senior Vice President,
Pfizer Pharmaceuticals Group, and Area President, Europe, will continue
in that position.
Additionally, Dr. McKinnell announced the
following new appointments:
- John W. Mitchell, will be named President,
Global Manufacturing. He is currently Senior Vice President, Global
Manufacturing.
- Ian C. Read, will be named Executive
Vice President, Europe, Pfizer Pharmaceuticals Group, reporting to
Mr. O'Connor. He is currently Senior Vice President, Pfizer Pharmaceuticals
Group, and Area President, Latin America/Canada. Canada will now report
to Mr. Read as part of the Pfizer Europe organization.
- Mohand A. Sidi Said, Vice President,
Pfizer Inc, Senior Vice President, Pfizer Pharmaceuticals Group, and
Area President, Asia/Africa/Middle East, will also have responsibility
for Latin America. The new Latin America management team will be named
shortly.
- R. Kent Snyder, President, Global Commercial
Operations, Agouron Pharmaceuticals, will continue in that position
and report to Karen Katen.
- Bernardo Tafur will be named to a senior
human resources position within the Pfizer Pharmaceuticals Group.
He is currently Vice President, Human Resources, Pharmaceuticals,
Warner-Lambert.
The following will also report to Dr. McKinnell:
- Brian W. Barrett, Vice President, Pfizer
Inc, and President, Animal Health Group, will continue in that position.
- Charles E. Hoover, President of the Capsugel
business of Warner-Lambert, will continue in that position.
- Frederick W. Telling, Ph.D., Vice President,
Corporate Strategic Planning & Policy, will continue in that position.
WARNER-LAMBERT CONSUMER DIVISION
Mr. Morton will be named President, Warner-Lambert
Consumer Division. The division's management team will be named by the
end of April.
PFIZER GLOBAL RESEARCH AND DEVELOPMENT
Dr. Niblack will be named President, Pfizer
Global Research and Development. The division will have three segments:
- Peter B. Corr, Ph.D., will be named Executive
Vice President, Pfizer Global Research and Development, and President,
Worldwide Development. The Worldwide Development group will ensure
clinical and regulatory excellence, and oversee the filing and launch
of late-stage candidates.
- John L. LaMattina, Ph.D., will be named
Executive Vice President, Pfizer Global Research and Development,
and President, Worldwide Research. The Worldwide Research group will
deliver significant compounds into the late development pipeline.
- George M. Milne, Jr., Ph.D., will be
named Executive Vice President, Pfizer Global Research and Development,
and President, Worldwide Strategic and Operations Management. The
Worldwide Strategic and Operations Management group will develop strategies
for continuing to meet our goals and implement the long-term organizational
changes needed for successful integration and the sustained productivity
of Pfizer personnel. The group will spearhead new technology and business
class platforms to ensure that our physical and financial resources
are optimally deployed. The Animal Health R&D group will continue
to report to Dr. Milne.
Pfizer Inc is a research-based global pharmaceutical
company that discovers, develops, manufactures and markets innovative
medicines for humans and animals. The company reported revenues of more
than $16 billion in 1999 and expects to spend about $3.2 billion on
research and development this year.
# # # #
|
